[go: up one dir, main page]

AR105836A1 - Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk - Google Patents

Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk

Info

Publication number
AR105836A1
AR105836A1 ARP160102616A ARP160102616A AR105836A1 AR 105836 A1 AR105836 A1 AR 105836A1 AR P160102616 A ARP160102616 A AR P160102616A AR P160102616 A ARP160102616 A AR P160102616A AR 105836 A1 AR105836 A1 AR 105836A1
Authority
AR
Argentina
Prior art keywords
cycloalkyl
alkylene
heterocyclyl
heteroalkyl
haloalkyl
Prior art date
Application number
ARP160102616A
Other languages
English (en)
Inventor
Bifulco Neil Jr
V Miduturu Chandrasekhar
Brooijmans Natasja
Mark Wenglowsky Steven
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of AR105836A1 publication Critical patent/AR105836A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Inhibidores de NTRK que son activos contra NTRK de tipo salvaje y sus mutantes resistentes. Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable de este, en donde: los anillos A y B se seleccionan cada uno independientemente de arilo, heteroarilo, cicloalquilo y heterociclilo; cada L¹ y L² se selecciona independientemente de un enlace, -C(O)-, -N(R¹)-, -N(R¹)-C(O)-, -C(O)-N(R¹)-, -(alquileno C₁₋₆)-N(R¹)-, -N(R¹)-(alquileno C₁₋₆)-, -N(R¹)-C(O)-(alquileno C₁₋₆)- y -C(O)-N(R¹)-(alquileno C₁₋₆)-; en donde cada parte de alquileno de L¹ y L² se sustituye independientemente con 0 - 5 apariciones de R’; cada RA y RB se selecciona independientemente de hidroxilo, alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, alcoxilo C₁₋₆, halo, heteroalquilo C₁₋₆, haloalquilo C₁₋₆, haloalcoxilo C₁₋₆, hidroxialquilo C₁₋₆, cicloalquilo, arilo, heteroarilo, ariloxi, aralquilo, heterociclilo, heterociclilalquilo, nitro, ciano, -C(O)R¹, -OC(O)R¹, -C(O)OR¹, -(alquileno C₁₋₆)-C(O)R¹, -SR¹, -S(O)₂R¹, -S(O)₂-N(R¹)(R¹), -(alquileno C₁₋₆)-S(O)₂R¹, -(alquileno C₁₋₆)-S(O)₂-N(R¹)(R¹), -N(R¹)(R¹), -C(O)-N(R¹)(R¹), -N(R¹)-C(O)R¹, -N(R¹)-C(O)OR¹, -(alquileno C₁₋₆)-N(R¹)-C(O)R¹, -N(R¹)S(O)₂R¹ y -P(O)(R¹)(R¹); en donde cada parte de alquilo alquenilo, .alquinilo, alcoxilo, heteroalquilo, haloalquilo, haloalcoxilo, hidroxialquilo, cicloalquilo, arilo, heteroarilo, ariloxi, aralquilo, heterociclilo y heterociclilalquilo de cada uno de RA y RB se sustituye independientemente con 0 - 5 apariciones de Rᵃ; o 2 RA o 2 RB juntos con el átomo de carbono al cual están unidos forman un anillo cicloalquilo o heterociclilo sustituido independientemente con 0 - 5 apariciones de Rᵃ; cada R¹ se selecciona independientemente de hidrógeno, hidroxilo, halo, tiol, alquilo C₁₋₆, tioalquilo C₁₋₆, alcoxilo C₁₋₆, haloalquilo C₁₋₆, hidroxialquilo C₁₋₆, heteroalquilo C₁₋₆, cicloalquilo, cicloalquilalquilo, heteroarilalquilo, heterociclilo y heterociclilalquilo, en donde cada parte de alquilo, tioalquilo, alcoxilo, haloalquilo, hidroxialquilo, heteroalquilo, cicloalquilo, cicloalquilalquilo, heteroarilalquilo, heterociclilo y heterociclilalquilo de R¹ se sustituye independientemente con 0 - 5 apariciones de Rᵇ o 2 R¹ junto con los átomos a los cuales están unidos forman un anillo cicloalquilo o heterociclilo sustituido independientemente con 0 - 5 apariciones de Rᵇ; cada Rᵃ y Rᵇ se selecciona independientemente de alquilo C₁₋₆, halo, hidroxilo, haloalquilo C₁₋₆, heteroalquilo C₁₋₆, hidroxialquilo C₁₋₆, alcoxilo C₁₋₆, cicloalquilo, heterociclilo y ciano, en donde cada parte de alquilo, haloalquilo, heteroalquilo, hidroxialquilo, alcoxilo, cicloalquilo y heterociclilo de Rᵃ y Rᵇ se sustituye independientemente con 0 - 5 apariciones de R’; cada R’ se selecciona independientemente de alquilo C₁₋₆, heteroalquilo C₁₋₆, halo, hidroxilo, haloalquilo C₁₋₆, hidroxialquilo C₁₋₆, cicloalquilo y ciano; o 2 R’ junto con el o los átomos a los que están unidos forman un anillo cicloalquilo o heterociclilo; y p es 0, 1, 2, 3, 4 ó 5; y q es 0, 1, 2, 3 ó 4.
ARP160102616A 2015-08-26 2016-08-26 Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk AR105836A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562210264P 2015-08-26 2015-08-26

Publications (1)

Publication Number Publication Date
AR105836A1 true AR105836A1 (es) 2017-11-15

Family

ID=56896780

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102616A AR105836A1 (es) 2015-08-26 2016-08-26 Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk

Country Status (17)

Country Link
US (2) US10017512B2 (es)
EP (1) EP3341374A1 (es)
JP (1) JP6877407B2 (es)
KR (1) KR20180043810A (es)
CN (1) CN108137607B (es)
AR (1) AR105836A1 (es)
AU (1) AU2016311426B2 (es)
BR (1) BR112018003588A2 (es)
CA (1) CA2995997A1 (es)
HK (1) HK1255330A1 (es)
IL (1) IL257702A (es)
MX (1) MX2018002407A (es)
PH (1) PH12018500397A1 (es)
RU (1) RU2744974C2 (es)
TW (1) TW201713665A (es)
WO (1) WO2017035354A1 (es)
ZA (1) ZA201801881B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2916220T3 (es) 2012-07-11 2022-06-29 Blueprint Medicines Corp Inhibidores del receptor de factor de crecimiento de fibroblasto
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
SG11201602937UA (en) 2013-10-17 2016-05-30 Blueprint Medicines Corp Compositions useful for treating disorders related to kit
SMT202200292T1 (it) 2013-10-25 2022-09-14 Blueprint Medicines Corp Inibitori del recettore del fattore di crescita dei fibroblasti
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
MX2018001032A (es) 2015-07-24 2018-11-09 Blueprint Medicines Corp Compuestos utiles para el tratamiento de trastornos relacionados con kit y pdgfr.
WO2017035354A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
JP2019500328A (ja) 2015-11-19 2019-01-10 ブループリント メディシンズ コーポレイション Ｎｔｒｋに関連する障害の治療のために有用な化合物及び組成物
WO2017161269A1 (en) 2016-03-17 2017-09-21 Blueprint Medicines Corporation Inhibitors of ret receptor tyrosine kinases
CA3020870C (en) 2016-04-15 2024-04-30 Blueprint Medicines Corporation Inhibitors of activin receptor-like kinase
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
US11040979B2 (en) 2017-03-31 2021-06-22 Blueprint Medicines Corporation Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
BR112020003783A2 (pt) 2017-08-23 2020-09-01 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. macrociclo contendo aminopirazol e pirimidina e composição farmacêutica e uso da mesma
JP7278273B2 (ja) 2017-10-18 2023-05-19 ブループリント メディシンズ コーポレイション アクチビン受容体様キナーゼの阻害剤としての置換ピロロピリジン
CN111936138B (zh) * 2018-02-05 2024-03-08 深圳市原力生命科学有限公司 作为ep4受体拮抗剂的杂二环化合物
BR112020019399A2 (pt) * 2018-03-28 2021-01-05 Fochon Pharmaceuticals, Ltd. Compostos macrocíclicos como inibidores de trk quinases
ES2970041T3 (es) 2018-04-03 2024-05-24 Blueprint Medicines Corp Inhibidor de RET para su uso en el tratamiento del cáncer que tiene una alteración de RET
AU2020228056A1 (en) * 2019-02-27 2021-09-16 Ferro Therapeutics, Inc. Compounds with ferroptosis inducing activity and methods of their use
RS64881B1 (sr) 2019-04-12 2023-12-29 Blueprint Medicines Corp Kristalini oblici (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-il)pirolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amin i načini pripreme
US11542276B2 (en) * 2019-11-25 2023-01-03 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
BR112022024382A2 (pt) 2020-05-29 2023-05-02 Blueprint Medicines Corp Formas sólidas de pralsetinibe
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
CN113408945B (zh) * 2021-07-15 2023-03-24 广西中烟工业有限责任公司 一种烤烟纯度的检测方法、装置、电子设备及存储介质

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0929553B1 (en) * 1996-10-02 2005-03-16 Novartis AG Pyrimidine derivatives and processes for the preparation thereof
PL224879B1 (pl) 2002-09-04 2017-02-28 Pharmacopeia Drug Discovery Inc Pirazolo [1,5-a] pirymidynowy związek, jego zastosowanie do wytwarzania leku oraz zawierająca go farmaceutyczna kompozycja
US7329662B2 (en) 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
CN102924458B (zh) * 2004-04-02 2014-11-05 Osi制药有限责任公司 6,6-双环取代的杂双环蛋白激酶抑制剂
CA2563699C (en) * 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
WO2009032703A1 (en) * 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
ES2900243T3 (es) 2008-10-22 2022-03-16 Array Biopharma Inc Compuestos de pirazolo[1,5-a]pirimidina sustituidos como inhibidores de trk quinasa
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
EP2566866A1 (en) * 2010-05-05 2013-03-13 Vertex Pharmaceuticals Incorporated 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
CN102241678B (zh) 2011-04-26 2014-10-29 辽宁利锋科技开发有限公司 含有脂环结构化合物的抗肿瘤作用与应用
ES2916220T3 (es) 2012-07-11 2022-06-29 Blueprint Medicines Corp Inhibidores del receptor de factor de crecimiento de fibroblasto
WO2014036387A2 (en) * 2012-08-31 2014-03-06 The Regents Of The University Of Colorado Methods for diagnosis and treatment of cancer
JP6457942B2 (ja) 2012-10-05 2019-01-23 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ−８阻害剤
HK1214830A1 (zh) 2012-11-05 2016-08-05 Foundation Medicine, Inc. 新型ntrk1融合分子及其应用
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
WO2014118226A1 (en) * 2013-02-01 2014-08-07 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyrimidinylamino-indazoles
CN103965199B (zh) 2013-02-02 2017-07-07 广东东阳光药业有限公司 一种芳杂环化合物、包含它的药物组合物及其用途
RU2672910C9 (ru) 2013-02-21 2019-06-04 Калитор Сайенсез, ЛЛС Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы
MX2015011898A (es) 2013-03-13 2016-05-05 Genentech Inc Compuestos de pirazolo y usos de los mismos.
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
GB2515785A (en) * 2013-07-03 2015-01-07 Redx Pharma Ltd Compounds
SG11201602937UA (en) 2013-10-17 2016-05-30 Blueprint Medicines Corp Compositions useful for treating disorders related to kit
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
SMT202200292T1 (it) 2013-10-25 2022-09-14 Blueprint Medicines Corp Inibitori del recettore del fattore di crescita dei fibroblasti
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
WO2015157093A1 (en) 2014-04-08 2015-10-15 Rigel Pharmaceuticals, Inc. 2,3-disubstituted pyridine compounds as tgf-beta inhibitors and methods of use
WO2016022569A1 (en) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
KR20240055170A (ko) 2014-12-15 2024-04-26 주식회사 씨엠지제약 융합된 고리 헤테로아릴 화합물 및 trk 억제제로서의 이들의 용도
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
JP6800158B2 (ja) 2015-02-20 2020-12-16 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｇｄｆ−８阻害剤
MX2018001032A (es) 2015-07-24 2018-11-09 Blueprint Medicines Corp Compuestos utiles para el tratamiento de trastornos relacionados con kit y pdgfr.
WO2017035354A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
JP2019500328A (ja) 2015-11-19 2019-01-10 ブループリント メディシンズ コーポレイション Ｎｔｒｋに関連する障害の治療のために有用な化合物及び組成物
WO2017161269A1 (en) 2016-03-17 2017-09-21 Blueprint Medicines Corporation Inhibitors of ret receptor tyrosine kinases
CA3020870C (en) 2016-04-15 2024-04-30 Blueprint Medicines Corporation Inhibitors of activin receptor-like kinase
US10227329B2 (en) 2016-07-22 2019-03-12 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
WO2018022761A1 (en) 2016-07-27 2018-02-01 Blueprint Medicines Corporation Substituted cyclopentane-amides for treating disorders related to ret
WO2018049233A1 (en) 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
CN107844168B (zh) 2017-11-23 2020-12-01 英业达科技有限公司 主板组件及其卡扣装置

Also Published As

Publication number Publication date
KR20180043810A (ko) 2018-04-30
RU2744974C2 (ru) 2021-03-17
US20170066773A1 (en) 2017-03-09
HK1255330A1 (zh) 2019-08-16
CN108137607A (zh) 2018-06-08
AU2016311426B2 (en) 2021-05-20
CA2995997A1 (en) 2017-03-02
IL257702A (en) 2018-04-30
US20190169194A1 (en) 2019-06-06
JP6877407B2 (ja) 2021-05-26
RU2018110379A (ru) 2019-09-27
BR112018003588A2 (pt) 2018-09-25
CN108137607B (zh) 2021-04-06
JP2018528200A (ja) 2018-09-27
AU2016311426A1 (en) 2018-04-05
PH12018500397A1 (en) 2018-08-29
MX2018002407A (es) 2018-11-29
WO2017035354A1 (en) 2017-03-02
RU2018110379A3 (es) 2019-12-26
US11046697B2 (en) 2021-06-29
TW201713665A (zh) 2017-04-16
ZA201801881B (en) 2019-05-29
US10017512B2 (en) 2018-07-10
EP3341374A1 (en) 2018-07-04

Similar Documents

Publication Publication Date Title
AR105836A1 (es) Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk
AR107912A1 (es) Inhibidores de ret
AR105459A1 (es) Derivados de pirrolo[2,1-f][1,2,4]triazina útiles para tratar trastornos relacionados con kit y pdfgr
CO2022008968A2 (es) Nuevos derivados de metilquinazolinona
AR085327A1 (es) Inhibidores del virus de la hepatitis c
AR094299A1 (es) Derivados de ftalazin-1(2h)-ona sustituidos
AR104388A1 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CO6251243A2 (es) Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR100233A1 (es) Composición de limpieza
AR106756A1 (es) Compuestos y composiciones útiles para el tratamiento de trastornos relacionados con ntrk
AR091285A1 (es) Inhibidores de bromodominio y sus usos
AR099955A1 (es) Compuestos de heteroarilo o arilo bicíclicos fusionados
AR101986A1 (es) Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso
AR098666A1 (es) Compuestos de biarilacetamida y sus métodos de uso
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR100807A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
CL2019001041A1 (es) Compuestos terapéuticos y métodos para utilizarlos.
AR107321A1 (es) Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
PH12017501652A1 (en) Kv1.3 inhibitors and their medical application
AR110440A1 (es) Compuestos para el tratamiento de la enfermedad respiratoria bovina o porcina
AR081893A1 (es) Derivados de acido 1-(2-fluorobifenil-4-il)-alquil carboxilico para la terapia de la amiloidosis transtiretina
AR109711A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
MX2018011721A (es) Compuesto de griseofulvina.
AR094804A1 (es) Compuesto de triazinona carboxamida o su sal

Legal Events

Date Code Title Description
FB Suspension of granting procedure